Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Assessing the effects of nucleotide-binding oligomerization domain-containing protein 1 stimulation: Novel target of therapy in models of Inflammatory Bowel Disease.

FY 2021-22

Summary
Inflammatory bowel disease (IBD) is a collection of conditions that result in the inflammation of the gastrointestinal tract causing diarrhea, abdominal pain, weight loss, nausea, and vomiting. With its prevalence a whopping 0.6% in Canada, there is a need for understanding targets of therapy for the disease. Crohns disease, which is one of the two main conditions implicated in IBD, is most often associated with polymorphisms in the nucleotide-binding oligomerization domain (NOD) 2 gene. NOD2 is integral to the innate immune system of mammals, and functions as a pattern recognition receptors (PRRs) within the cytosol of cells. It detects conserved bacterial peptidoglycans (PGN) to elicit an anti-microbial response by activating the nuclear factor kappa B (NF-B) pathway. Crohns disease patients have defective barrier function in intestinal paneth cells due to this polymorphism, and bacteria are able to colonize the intestine leading to inflammation. Interestingly, NOD1 and NOD2 have similar downstream effects when activated by their ligands: inducing the NF-B pathway. Little research has been done to examine the effects of stimulating NOD1 in the absence of NOD2. Should the stimulation of NOD1 rectify the Crohns disease phenotype, this research can provide insight on possible targets for therapy. This research aims to examine the effects of NOD1 stimulation in NOD2 -/- organoids. RNA sequence data will be collected with the ligand stimulation under these conditions. Transcription profiles of treated and untreated NOD2-/- and wildtype organoids will be compared to assess the efficacy of NOD1 stimulation as a target for IBS therapy.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
466573
Name
Nissan Marry A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Assessing the effects of nucleotide-binding oligomerization domain-containing protein 1 stimulation: Novel target of therapy in models of Inflammatory Bowel Disease.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Ibd; Ie-Dap; Ifn?; Inflammatory Bowel Disease; Interferon-?; Nf-?B; Nod1; Nod2; Nuclear Factor Kappa B; Nucleotide-Binding Oligomerization Domain
Abstract
Inflammatory bowel disease (IBD) is a collection of conditions that result in the inflammation of the gastrointestinal tract causing diarrhea, abdominal pain, weight loss, nausea, and vomiting. With its prevalence a whopping 0.6% in Canada, there is a need for understanding targets of therapy for the disease. Crohns disease, which is one of the two main conditions implicated in IBD, is most often associated with polymorphisms in the nucleotide-binding oligomerization domain (NOD) 2 gene. NOD2 is integral to the innate immune system of mammals, and functions as a pattern recognition receptors (PRRs) within the cytosol of cells. It detects conserved bacterial peptidoglycans (PGN) to elicit an anti-microbial response by activating the nuclear factor kappa B (NF-B) pathway. Crohns disease patients have defective barrier function in intestinal paneth cells due to this polymorphism, and bacteria are able to colonize the intestine leading to inflammation. Interestingly, NOD1 and NOD2 have similar downstream effects when activated by their ligands: inducing the NF-B pathway. Little research has been done to examine the effects of stimulating NOD1 in the absence of NOD2. Should the stimulation of NOD1 rectify the Crohns disease phenotype, this research can provide insight on possible targets for therapy. This research aims to examine the effects of NOD1 stimulation in NOD2 -/- organoids. RNA sequence data will be collected with the ligand stimulation under these conditions. Transcription profiles of treated and untreated NOD2-/- and wildtype organoids will be compared to assess the efficacy of NOD1 stimulation as a target for IBS therapy.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nissan, Marry A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~